Suppr超能文献

[手术在甲状腺淋巴瘤治疗中的作用]

[The role of surgery in the management of thyroid lymphoma].

作者信息

Li Z, Tang P, Huang Y

机构信息

Department of Head and Neck Surgery, Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing 100021.

出版信息

Zhonghua Zhong Liu Za Zhi. 1999 Nov;21(6):464-6.

Abstract

OBJECTIVE

To evaluate the role of surgery in the management of thyroid lymphoma.

METHODS

A retrospective analysis was performed of 14 patients with thyroid lymphoma treated at the Cancer Hospital, Peking Union Medical College, Chinese Academy Medical Science from 1964 to March 1998. There were 5 males and 9 females, with a median age of 54 years (range 15-75). There were 4 cases in stage IEA, 9 in stage IIEA, 1 in stage II EB. Fine needle aspiration biopsy was performed in 1 case, excision biopsy in 4, thyroid lobectomy in 8, and total thyroidectomy in 1. Radiotherapy was used alone in 4 patients, chemotherapy alone in 2, radiotherapy combined with chemotherapy in 7, no postoperative treatment in 1.

RESULTS

All but 1 patients were histopathologically diagnosed as non-Hodgkin's lymphoma. It was of B cell origin in 11 cases, T cell origin in 2. Seven patients were alive without evidence of recurrent disease at follow-up, ranging from 5 to 112 months. Three patients died of lymphoma, 1 died of treatment complication, 2 died of other diseases, and 1 lost from follow-up. The major surgical resection did not appreciably affect survival.

CONCLUSION

Radiotherapy or chemotherapy, alone or in combination, is the treatment of choice for thyroid lymphoma. Surgical resection combined with radiotherapy or chemotherapy may be beneficial to survival in patients with intrathyroid lymphoma. It is otherwise limited to make a tissue diagnosis.

摘要

目的

评估手术在甲状腺淋巴瘤治疗中的作用。

方法

对1964年至1998年3月在中国医学科学院北京协和医院肿瘤医院接受治疗的14例甲状腺淋巴瘤患者进行回顾性分析。其中男性5例,女性9例,中位年龄54岁(范围15 - 75岁)。IEA期4例,IIEA期9例,IIEB期1例。1例行细针穿刺活检,4例行切除活检,8例行甲状腺叶切除术,1例行甲状腺全切除术。4例患者单纯接受放疗,2例单纯接受化疗,7例接受放疗联合化疗,1例未进行术后治疗。

结果

除1例患者外,所有患者经组织病理学诊断为非霍奇金淋巴瘤。其中11例为B细胞起源,2例为T细胞起源。7例患者在随访期间存活,无疾病复发迹象,随访时间为5至112个月。3例患者死于淋巴瘤,1例死于治疗并发症,2例死于其他疾病,1例失访。主要手术切除对生存率无明显影响。

结论

放疗或化疗,单独或联合应用,是甲状腺淋巴瘤的首选治疗方法。手术切除联合放疗或化疗可能对甲状腺内淋巴瘤患者的生存有益。否则,手术仅限于进行组织诊断。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验